Mesenkia Therapeutics is a Swedish-Japanese preclinical biotechnology company developing KITAIbodies®, modular single-domain antibodies directed at HVEM, a signaling pathway implicated in glioblastoma and other cancers. Its lead program seeks to treat aggressive glioblastoma by combining HVEM-targeting antibodies with technologies that transport therapeutics across the blood-brain barrier. The company develops drug candidates through its proprietary antibody platform and research collaborations; its products are in preclinical development.
